Sin conexión a internet: se muestra la versión guardada de la página.

Soligenix Inc.

USUSD
← Al Screener

Soligenix Inc. (LSE:0A6I) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
soligenix.com
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Sede Central
PRINCETON, United States
Consejero Delegado
Christopher J. Schaber
Empleados
13
Cotiza Desde
04.03.2021 (LSE:0A6I)
Acciones en Circulación
21.77 M a 2026-07-31
1 Año: +245.9% · 3 años: +0.3% · 5 años: +263.9% (sin contar los splits)
FechaAccionesCambio
31.07.202621.77 Msplit 1.5:1
01.05.202614.82 M+43.8%emisión (dilución)
24.03.202610.31 M+2.2%emisión (dilución)
31.10.202510.09 M+135.4%emisión (dilución)
07.08.20254.29 M+31.3%emisión (dilución)
02.05.20253.26 M+3.4%emisión (dilución)
14.03.20253.16 M+25.7%emisión (dilución)
01.11.20242.51 M+10.0%emisión (dilución)
02.08.20242.28 M−85.6%recompra
03.05.202415.8 Msplit 1.5:1
08.03.202410.52 M+1.4%emisión (dilución)
06.11.202310.38 M+5.5%emisión (dilución)
14.08.20239.84 M+21.3%emisión (dilución)
09.05.20238.12 M+177.5%emisión (dilución)
24.03.20232.92 Mcontrasplit 1:15
Número de acciones según los informes de la empresa. Un split se detecta por un salto del número en un múltiplo entero.
Capital Flotante
21.66 M
Capitalización Bursátil
7.91 M USD
Insiders
4.59%
Inversores Institucionales
6.72%
Industria (SIC)
Pharmaceutical Preparations
P/E
pérdidas
FCF
−10.3 M USD
Deuda
0 USD
Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
Descripción

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksSNGX principalUSD0.3636 +4.90%acciones ordinarias
LSE London Stock Exchange0A6I IOBUSD0.36 +0.00%acciones ordinarias

Precio en 3 Meses

día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Citadel Advisors Llc0.96%209 5072026-06-30
Jane Street Group, LLC0.95%207 4922026-06-30
Xtx Topco Ltd0.72%157 1192026-06-30
Geode Capital Management…0.55%120 2672026-06-30
Vanguard Capital Managem…0.37%81 0052026-06-30
VANGUARD INDEX FUNDS-Van…0.37%81 0052026-06-30
Fidelity Concord Street…0.35%76 1762026-07-31
Virtu Financial LLC0.28%60 9032026-06-30
Vanguard Fiduciary Trust…0.25%53 9142026-06-30
Northern Trust Corporati…0.17%38 0462026-06-30
SCHABER CHRISTOPHER J (C…≈0.07%15 5112025-10-02
Fidelity Concord Street…0.07%14 4592026-07-31
Fidelity Concord Street…0.04%8 0542026-07-31
Morgan Stanley0.02%3 5922026-06-30
Jones Financial Companie…0.01%1 2362026-06-30